KR20120056267A - 전립선 암의 치료 - Google Patents

전립선 암의 치료 Download PDF

Info

Publication number
KR20120056267A
KR20120056267A KR1020127006009A KR20127006009A KR20120056267A KR 20120056267 A KR20120056267 A KR 20120056267A KR 1020127006009 A KR1020127006009 A KR 1020127006009A KR 20127006009 A KR20127006009 A KR 20127006009A KR 20120056267 A KR20120056267 A KR 20120056267A
Authority
KR
South Korea
Prior art keywords
compound
composition
administration
dose
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020127006009A
Other languages
English (en)
Korean (ko)
Inventor
조디 포프 모리슨
사이러스 아론 스테인
데이비 스콧 케세비어
Original Assignee
토카이 파마슈티컬, 아이엔씨.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 토카이 파마슈티컬, 아이엔씨. filed Critical 토카이 파마슈티컬, 아이엔씨.
Publication of KR20120056267A publication Critical patent/KR20120056267A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020127006009A 2009-08-07 2010-08-05 전립선 암의 치료 Ceased KR20120056267A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23225709P 2009-08-07 2009-08-07
US61/232,257 2009-08-07
US26126509P 2009-11-13 2009-11-13
US61/261,265 2009-11-13
PCT/US2010/044570 WO2011017534A2 (en) 2009-08-07 2010-08-05 Treatment of prostate cancer

Publications (1)

Publication Number Publication Date
KR20120056267A true KR20120056267A (ko) 2012-06-01

Family

ID=43535282

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127006009A Ceased KR20120056267A (ko) 2009-08-07 2010-08-05 전립선 암의 치료

Country Status (8)

Country Link
US (5) US8791094B2 (enExample)
EP (1) EP2461814A4 (enExample)
JP (2) JP2013501722A (enExample)
KR (1) KR20120056267A (enExample)
AU (1) AU2010279398A1 (enExample)
BR (1) BR112012002797A2 (enExample)
CA (1) CA2770092A1 (enExample)
WO (1) WO2011017534A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8785423B2 (en) * 2008-04-14 2014-07-22 University Of Maryland, Baltimore Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
EP2393827B1 (en) 2009-02-05 2015-10-07 Tokai Pharmaceuticals, Inc. Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
WO2010149755A1 (en) 2009-06-26 2010-12-29 Novartis Ag 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
CA2841960A1 (en) * 2011-07-18 2013-01-24 Tokai Pharmaceuticals, Inc. Novel compositions and methods for treating prostate cancer
AU2012294570B2 (en) * 2011-08-05 2015-09-10 Gen-Probe Incorporated Antiandrogen therapy monitoring methods and compositions
WO2013071177A1 (en) * 2011-11-10 2013-05-16 Tokai Pharmaceuticals, Inc. Methods and compositions for inhibition of androgen receptor activity
SG11201507093WA (en) 2013-03-14 2015-10-29 Univ Maryland Baltimore Office Of Technology Transfer Androgen receptor down-regulating agents and uses thereof
SG11201600525XA (en) 2013-08-12 2016-02-26 Tokai Pharmaceuticals Inc Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
WO2015170336A1 (en) 2014-05-09 2015-11-12 Council Of Scientific & Industrial Research 16α-HETEROARYL PREGNENOLONE ACETATE AND A PROCESS FOR PREPARATION THEREOF
WO2016119742A1 (zh) * 2015-01-29 2016-08-04 苏州晶云药物科技有限公司 (3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
ITUA20164043A1 (it) * 2016-06-01 2017-12-01 Ind Chimica Srl Processo per la preparazione di 3β-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene
ES2697706R1 (es) * 2016-06-01 2019-02-08 Ind Chimica Srl Proceso Para La Preparación De Galeterona.
AU2019287541A1 (en) * 2018-06-14 2021-01-21 Astrazeneca Uk Limited Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition
CN114072414A (zh) * 2019-04-27 2022-02-18 健康研究股份有限公司 用于治疗前列腺癌的香豆素修饰的雄激素

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621803A5 (enExample) * 1974-08-08 1981-02-27 Siphar Sa
US5604213A (en) * 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
NZ266640A (en) * 1993-04-30 1998-01-26 Pacific Northwest Research Fou Diagnosing genotoxic or carcinogenic status by analysing cellular redox potential where increased risk is indicated when the potential favours oxidatively derived modified nucleotides
US5994335A (en) * 1997-10-17 1999-11-30 The University Of Maryland, Baltimore 17-azolyl steroids useful as androgen synthesis inhibitors
US20030054053A1 (en) * 2001-09-20 2003-03-20 Charles Young Methods and compositions for inhibiting the proliferation of prostate cancer cells
ES2369487T3 (es) 2003-07-29 2011-12-01 Dompe' S.P.A. Combinación farmacéutica de g-csf y plgf útil para células madre de sangre.
JP4585201B2 (ja) * 2004-01-23 2010-11-24 丸善製薬株式会社 アンドロゲン受容体結合阻害剤、養毛剤、皮脂分泌抑制剤及び前立腺肥大抑制剤
DK2206719T3 (en) * 2005-03-02 2015-01-26 Univ Maryland A pharmaceutical composition comprising 3-BETA-HYDROXY-17- (1-H-benzimidazol-1-yl) androsta-5, 16-DIEN
WO2008154382A1 (en) 2007-06-06 2008-12-18 University Of Maryland, Baltimore Hdac inhibitors and hormone targeted drugs for the treatment of cancer
US20100048913A1 (en) * 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
WO2011017534A2 (en) 2009-08-07 2011-02-10 Tokai Pharmaceuticals, Inc. Treatment of prostate cancer

Also Published As

Publication number Publication date
JP2013501722A (ja) 2013-01-17
BR112012002797A2 (pt) 2019-09-24
US20140343024A1 (en) 2014-11-20
US9156878B2 (en) 2015-10-13
EP2461814A2 (en) 2012-06-13
US20110034428A1 (en) 2011-02-10
EP2461814A4 (en) 2012-12-05
AU2010279398A1 (en) 2012-03-08
US20150166599A1 (en) 2015-06-18
US8791094B2 (en) 2014-07-29
US20150203528A1 (en) 2015-07-23
WO2011017534A3 (en) 2011-06-30
US20170157148A1 (en) 2017-06-08
WO2011017534A2 (en) 2011-02-10
CA2770092A1 (en) 2011-02-10
JP2016074687A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
US8791094B2 (en) Treatment of prostate cancer
US9387216B2 (en) Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
CN103813794A (zh) 用于治疗前列腺癌的新型组合物及方法
JP2001354590A (ja) 良性前立腺過形成の予防および／または治療のための組合せ療法
US20020123485A1 (en) Epoxy steroidal aldosterone antagonist and beta-adrenergic antagonist combination therapy for treatment of congestive heart failure
JP2004507495A (ja) 認知機能改善のためのアルドステロン受容体拮抗薬の使用
US20250352531A1 (en) Dosage Regimen for the Treatment of Cancer
JP2020530026A (ja) 線維性疾患の治療における使用のための化合物及びその医薬組成物
JP2002538172A (ja) 循環器疾患治療のためのアンギオテンシン変換酵素阻害薬およびエポキシ−ステロイドアルドステロン拮抗薬の組合せ療法
CN110352058A (zh) 相伴给予糖皮质激素受体调节剂和cyp3a抑制剂
WO2021180055A1 (zh) 一种brd4抑制剂的用途
US20230338351A1 (en) Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic Impairment
Boccardo et al. Clinical efficacy and endocrine activity of vorozole in postmenopausal breast cancer patients. Results of a multicentric phase II study
HK40085111A (en) Dosage regimen for the treatment of cancer
WO2024076633A1 (en) Methods of treating estrogen receptor-mediated disorders
WO2024006207A1 (en) An n-terminal domain androgen receptor inhibitor and uses thereof
HK40087811A (zh) 用於治疗具有严重肝损伤的受试者的非转移性去势抵抗性前列腺癌的雄激素受体抑制剂

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120306

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150730

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160920

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20170327

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160920

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I